Pharmacokinetics of the CYP 3A substrate simvastatin following administration of delayed versus immediate release oral dosage forms.

Pharmaceutical Research
Marija Tubic-GrozdanisPeter Langguth

Abstract

The study was designed to evaluate the effect of delayed release (DR) on absorption and bioavailability of intestinally metabolized drugs after oral dosing, using the HMG-CoA reductase inhibitor simvastatin, a CYP3A substrate, as a model drug. To target drug release and to assess regional gastrointestinal absorption of the CYP 3A substrate simvastatin from the distal parts of the intestine, delayed release film coated tableted oral dosage forms were developed. Simvastatin delayed release tablet, simvastatin immediate release capsule and simvastatin immediate release tablet Zocor were administered as single doses (20 mg) to fasting healthy volunteers in a crossover design. Simvastatin bioavailability was increased by a factor of three, as compared to the reference formulation Zocor. The overall metabolite levels from the immediate release capsules tended to be higher throughout the period studied than the metabolite levels following administration of Zocor and simvastatin delayed release dosage form. The interplay between gastrointestinal physiology (lower CYP 3A expression in the distal ileum and the colon) and formulation design (zero-order controlled release after a predetermined lag-time) resulted in successful absorption an...Continue Reading

References

May 1, 1988·Journal of Clinical Pharmacology·J M ScavoneR I Shader
Nov 1, 1984·Clinical Pharmacology and Therapeutics·G P StoehrR B Smith
Oct 1, 1982·Journal of Pharmacokinetics and Biopharmaceutics·K K Chan, M Gibaldi
Oct 1, 1994·Pharmacogenetics·J C KolarsP B Watkins
May 1, 1996·Clinical Pharmacology and Therapeutics·K E ThummelG R Wilkinson
Oct 3, 1998·Clinical Pharmacology and Therapeutics·D G BaileyJ R Bend
Mar 31, 2000·Clinical Pharmacology and Therapeutics·O MousaS D Hall
Mar 14, 2002·International Journal of Pharmaceutics·Howard N E StevensSteve R Wicks
Mar 19, 2002·International Journal of Pharmaceutics·J J SousaJ M Newton
Apr 16, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomayant PrueksaritanontThomas A Baillie
Jun 7, 2002·The American Journal of Medicine·Michael H Davidson, UNKNOWN National cholesterol Education Program (NCEP) Adult Treatment Panel (ATP)--ATP III Guidelines
Sep 3, 2002·International Journal of Pharmaceutics·Marja SavolainenAnne Mari Juppo
Mar 28, 2003·Journal of Pharmaceutical Sciences·Toyohiro SawadaMasahiro Hayashi
Jul 10, 2003·British Journal of Clinical Pharmacology·Thomayant PrueksaritanontNathan Yu
Aug 21, 2003·International Journal of Pharmaceutics·Marja SavolainenAnne Mari Juppo
Jun 21, 2005·British Journal of Clinical Pharmacology·Mari ThörnLars Lööf
Sep 16, 2005·Drugs·Abdul W Basit
Mar 15, 2006·Current Pharmaceutical Design·Rosario CalvoElena Suarez
Apr 20, 2006·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Mine OzyaziciGökhan Ertan
Nov 17, 2006·Pharmacogenetics and Genomics·Marja K PasanenMikko Niemi

❮ Previous
Next ❯

Citations

Dec 24, 2014·Journal of Microencapsulation·Jayvadan K Patel, Vijaykumar B Sutariya
Jun 27, 2009·Journal of Drug Targeting·Emma L McConnellAbdul W Basit
Nov 19, 2008·Journal of Drug Targeting·Abdul W BasitEmma L McConnell
May 20, 2015·Journal of Pharmaceutical Sciences·Shinji SakumaKohsaku Kawakami
Oct 7, 2009·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Rainer CermakPeter Langguth
Dec 3, 2014·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Andrés Olivares-MoralesAmin Rostami-Hodjegan
Jul 8, 2008·International Journal of Pharmaceutics·Emma L McConnellAbdul W Basit
Jun 12, 2012·Pharmaceutical Development and Technology·Yellela S R Krishnaiah, Mansoor A Khan
Jul 5, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Aki T HeikkinenNeil Parrott
Mar 5, 2013·Journal of Controlled Release : Official Journal of the Controlled Release Society·C VitorinoA A C C Pais
Feb 4, 2010·The Annals of Pharmacotherapy·Tanner W Higginbotham
May 7, 2010·Clinical Pharmacology and Therapeutics·I B SkottheimR Sandbu
Dec 13, 2017·Drug Development and Industrial Pharmacy·Zora ĆetkovićDragana Vasiljević
Jan 7, 2019·Molecular Biology Reports·Carolina Arruda de FariaJoão Tadeu Ribeiro-Paes
Apr 17, 2020·Pharmaceutics·Juliane Fjelrad ChristfortLine Hagner Nielsen
Dec 15, 2019·International Journal of Pharmaceutics·Annelies SmeetsGuy Van den Mooter
Mar 7, 2021·Pharmaceutics·Arik Dahan, Isabel González-Álvarez
Apr 24, 2021·Expert Opinion on Drug Metabolism & Toxicology·Panagiotis-Nikolaos LalagkasAntonios Douros
May 14, 2021·Colloids and Surfaces. B, Biointerfaces·Aleksandra BartkowiakRenata Bilewicz
Jun 3, 2021·Biomedicines·Vipul YadavAbdul W Basit

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.